KOPRAN. share price has zoomed 5% and is presently trading at Rs 313.9.
Meanwhile, the BSE HEALTHCARE index is at 44,564.6 (down 0.2%).
Among the top gainers in the BSE HEALTHCARE index today are Pfizer (up 2.2%) and GSK Pharma (up 2.1%).
Torrent Pharma (down 1.7%) and Jubilant Pharmova (down 1.3%) are among the top losers today.
Over the last one year, KOPRAN. has moved up from Rs 224.0 to Rs 313.9, registering a gain of Rs 89.9 (up 40.1%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,166.2 to 44,564.6, registering a gain of 58.2% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 198.8%), Glenmark Pharma (up 122.4%) and SUVEN PHARMACEUTICALS (up 114.3%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 81,205.7 (down 0.4%).
The top losers among the BSE Sensex today are M&M (down 2.5%) and Maruti Suzuki (down 1.9%). The most traded stocks in the BSE Sensex are Tata Steel and SBI.
In the meantime, NSE Nifty is at 24,821.7 (down 0.6%). Bajaj Auto and Hero Motocorp are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,166.9 to 81,205.7, registering a gain of 15,038.7 points (up 22.7%).
KOPRAN. net profit grew 300.1% YoY to Rs 111 million for the quarter ended June 2024, compared to a profit of Rs 28 million a year ago. Net sales rose 19.2% to Rs 1,394 million during the period as against Rs 1,170 million in April-June 2023.
For the year ended March 2024, KOPRAN. reported 87.1% increase in net profit to Rs 510 million compared to net profit of Rs 272 million during FY23. Revenue of the company grew 11.5% to Rs 6,146 million during FY24.
The current Price to earnings ratio of KOPRAN., based on rolling 12 month earnings, stands at 25.5.
Equitymaster requests your view! Post a comment on "KOPRAN. Gains 5%; BSE HEALTHCARE Index Down 0.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!